Figure 3.
Overall survival analysis in stage II and III CRC patients treated with oxaliplatin-based chemotherapy according to methylation status of RASSF1A. Patients without RASSF1A methylation had a favorable prognosis, compared with those with methylation (31.66 months versus 25.90 months, log rank test, p=0.006).